Loading
Pharmaceutical
9 min read
Areas of Expertise :
Food And Drug Administration (FDA), Pharmaceutical, Labels And Warnings, Product Liability, Pharmacology
Published Date:
Last Modified Date:
Jurisdiction:
Federal. U.S. Supreme Court
Court:
In the landmark case Wyeth v. Levine, the U.S. Supreme Court addressed whether federal drug labeling regulations shield pharmaceutical companies from state-level liability. The dispute arose after Diana Levine, a Vermont musician, suffered the amputation of her forearm following an intravenous push (IV-push) injection of Phenergan, an anti-nausea drug manufactured by Wyeth. Though the drug’s label warned of risks associated with arterial exposure, Levine argued that the warning was insufficient and failed to instruct against the high-risk IV-push method. A Vermont jury agreed and awarded her $7.4 million in damages, later reduced due to prior settlements. Wyeth appealed, asserting that federal law preempted Levine’s failure-to-warn claims under state tort law.
The central issue before the U.S. Supreme Court was whether the Food and Drug Administration’s (FDA) approval of Phenergan’s labeling preempted state failure-to-warn claims. Wyeth contended it was impossible to comply with both federal labeling regulations and state-imposed duties. However, the Court rejected this argument, holding that the FDA’s labeling requirements provide a minimum standard, and that drug manufacturers retain the responsibility to strengthen warnings when new safety concerns arise. The ruling emphasized that FDA approval does not absolve manufacturers from liability under state law, particularly when they could have used the FDA’s “Changes Being Effected” (CBE) regulation to independently enhance the label to better protect patients.
Diana Levine, a musician from Vermont, sought treatment at a local health clinic for migraine-related nausea. She was first given an intramuscular injection of the anti-nausea drug Phenergan, manufactured by Wyeth. When symptoms persisted, a second dose was administered using the IV-push method, which involves direct injection into a vein. The drug inadvertently entered an artery, causing severe tissue damage that led to gangrene. Levine ultimately required the amputation of her right forearm.
Levine filed a state-law damages lawsuit against Wyeth in Vermont, claiming the company failed to adequately warn against the risks of administering Phenergan via IV-push. While the FDA-approved label included general cautions about accidental arterial injection, it did not explicitly discourage the IV-push method or advise safer alternatives like IV-drip. Levine argued that the labeling was defective and directly contributed to her permanent injury.
A Vermont jury found Wyeth liable for negligence and failure to warn, awarding Levine $7.4 million in damages. The jury concluded that Wyeth’s labeling did not adequately warn of the dangers associated with IV-push administration. After trial, both parties agreed to reduce the final amount to $6.77 million to account for pre-judgment interest and Levine’s prior settlement with the clinic. The stipulation indicated that Levine accepted the reduced award, bringing the damages phase of the litigation to a close. Wyeth continued to challenge the verdict on legal grounds.
Wyeth appealed, asserting that federal law preempted state tort claims due to the FDA’s approval of Phenergan’s label. The Vermont Supreme Court rejected this argument, holding that federal labeling regulations set a minimum standard and do not prevent manufacturers from enhancing warnings on their own initiative. The Court emphasized that under the FDA’s “Changes Being Effected” (CBE) regulation, Wyeth could have unilaterally strengthened its warnings without prior FDA approval. As such, Levine’s state-law claims were not preempted, and the jury’s verdict stood.
Wyeth petitioned the U.S. Supreme Court for certiorari, asking it to resolve whether FDA labeling approval preempts state failure-to-warn claims. The Court granted review, recognizing the case’s national significance in clarifying the scope of FDA authority versus state liability laws. The central legal issue became whether a drug manufacturer could be held accountable under state law even when its label had been reviewed and approved by the FDA.
In a 6–3 decision, the Supreme Court affirmed the Vermont Supreme Court’s ruling in favor of Levine. Writing for the majority, Justice John Paul Stevens held that FDA drug labeling regulations do not preempt state-law failure-to-warn claims. The Court concluded that Wyeth could have added a stronger warning about IV-push risks through the CBE process without violating federal law. The ruling underscored that drug manufacturers, not the FDA, are ultimately responsible for ensuring their labels reflect known safety risks. The Court rejected Wyeth’s argument that state tort claims undermined the FDA’s authority.
With the U.S. Supreme Court’s decision, the litigation formally concluded in favor of Diana Levine. The Court’s ruling established that FDA approval of a drug label does not shield manufacturers from state-level liability for inadequate warnings. This decision became a defining precedent in drug injury litigation, reinforcing the role of state tort law as a safeguard for consumer health alongside federal regulation.
Supreme Court of the United States
Case Name:
Wyeth v. Levine
Drug Labels
FDA Regulation
Drug Regulation
Pharmaceutical Product Liability
Safety Warnings
Adverse Event
Drug Research
Pharmacotherapy
In the landmark case Wyeth v. Levine, the U.S. Supreme Court addressed whether federal drug labeling regulations shield pharmaceutical companies from state-level liability. The dispute arose after Diana Levine, a Vermont musician, suffered the amputation of her forearm following an intravenous push (IV-push) injection of Phenergan, an anti-nausea drug manufactured by Wyeth. Though the drug’s label warned of risks associated with arterial exposure, Levine argued that the warning was insufficient and failed to instruct against the high-risk IV-push method. A Vermont jury agreed and awarded her $7.4 million in damages, later reduced due to prior settlements. Wyeth appealed, asserting that federal law preempted Levine’s failure-to-warn claims under state tort law.
The central issue before the U.S. Supreme Court was whether the Food and Drug Administration’s (FDA) approval of Phenergan’s labeling preempted state failure-to-warn claims. Wyeth contended it was impossible to comply with both federal labeling regulations and state-imposed duties. However, the Court rejected this argument, holding that the FDA’s labeling requirements provide a minimum standard, and that drug manufacturers retain the responsibility to strengthen warnings when new safety concerns arise. The ruling emphasized that FDA approval does not absolve manufacturers from liability under state law, particularly when they could have used the FDA’s “Changes Being Effected” (CBE) regulation to independently enhance the label to better protect patients.
Diana Levine, a musician from Vermont, sought treatment at a local health clinic for migraine-related nausea. She was first given an intramuscular injection of the anti-nausea drug Phenergan, manufactured by Wyeth. When symptoms persisted, a second dose was administered using the IV-push method, which involves direct injection into a vein. The drug inadvertently entered an artery, causing severe tissue damage that led to gangrene. Levine ultimately required the amputation of her right forearm.
Levine filed a state-law damages lawsuit against Wyeth in Vermont, claiming the company failed to adequately warn against the risks of administering Phenergan via IV-push. While the FDA-approved label included general cautions about accidental arterial injection, it did not explicitly discourage the IV-push method or advise safer alternatives like IV-drip. Levine argued that the labeling was defective and directly contributed to her permanent injury.
A Vermont jury found Wyeth liable for negligence and failure to warn, awarding Levine $7.4 million in damages. The jury concluded that Wyeth’s labeling did not adequately warn of the dangers associated with IV-push administration. After trial, both parties agreed to reduce the final amount to $6.77 million to account for pre-judgment interest and Levine’s prior settlement with the clinic. The stipulation indicated that Levine accepted the reduced award, bringing the damages phase of the litigation to a close. Wyeth continued to challenge the verdict on legal grounds.
Wyeth appealed, asserting that federal law preempted state tort claims due to the FDA’s approval of Phenergan’s label. The Vermont Supreme Court rejected this argument, holding that federal labeling regulations set a minimum standard and do not prevent manufacturers from enhancing warnings on their own initiative. The Court emphasized that under the FDA’s “Changes Being Effected” (CBE) regulation, Wyeth could have unilaterally strengthened its warnings without prior FDA approval. As such, Levine’s state-law claims were not preempted, and the jury’s verdict stood.
Wyeth petitioned the U.S. Supreme Court for certiorari, asking it to resolve whether FDA labeling approval preempts state failure-to-warn claims. The Court granted review, recognizing the case’s national significance in clarifying the scope of FDA authority versus state liability laws. The central legal issue became whether a drug manufacturer could be held accountable under state law even when its label had been reviewed and approved by the FDA.
In a 6–3 decision, the Supreme Court affirmed the Vermont Supreme Court’s ruling in favor of Levine. Writing for the majority, Justice John Paul Stevens held that FDA drug labeling regulations do not preempt state-law failure-to-warn claims. The Court concluded that Wyeth could have added a stronger warning about IV-push risks through the CBE process without violating federal law. The ruling underscored that drug manufacturers, not the FDA, are ultimately responsible for ensuring their labels reflect known safety risks. The Court rejected Wyeth’s argument that state tort claims undermined the FDA’s authority.
With the U.S. Supreme Court’s decision, the litigation formally concluded in favor of Diana Levine. The Court’s ruling established that FDA approval of a drug label does not shield manufacturers from state-level liability for inadequate warnings. This decision became a defining precedent in drug injury litigation, reinforcing the role of state tort law as a safeguard for consumer health alongside federal regulation.
Drug Labels Expert Witness
Drug Label Experts assessed whether the Phenergan label adequately communicated the risks associated with IV-push administration. They analyzed the content, clarity, and prominence of the warning language, focusing on whether the label sufficiently informed clinicians of known dangers.
The plaintiff’s expert argued that the label should have explicitly discouraged IV-push use, while Wyeth’s expert maintained that the FDA-approved language was appropriate. Their testimony centered on how stronger or more specific warnings might have altered the method of drug administration and prevented harm.
Medical Expert Witness
Medical Experts in Wyeth v. Levine provided testimony on the technical risks of intravenous drug delivery, focusing on whether the IV-push method posed foreseeable vascular hazards. These experts did not assess treatment errors or standard of care broadly but instead evaluated how administration techniques interact with drug characteristics and labeling. Their role was critical in connecting label warnings to the resulting physical injury. While their domain overlaps with clinical practice, their involvement in this case was limited to drug safety and administration protocol.
Food and Drug Administration (FDA) Expert Witness
FDA experts are often engaged in drug labeling litigation to clarify how Food and Drug Administration processes affect manufacturer responsibilities. In such cases, the legal debate centered on whether FDA approval of Phenergan’s label preempted state failure-to-warn claims, with key focus on the “Changes Being Effected” (CBE) regulation. Litigation of this nature often involves former FDA staff or regulatory consultants to explain the agency’s approval authority, preemption stance, and risk communication standards.
Drug Research Expert Witness
Drug research experts are commonly engaged in pharmaceutical litigation to assess how adverse events are monitored, reported, and acted upon during a drug’s life cycle. These experts often examine post-marketing surveillance data, FDA safety reporting practices, and clinical pharmacology to evaluate whether warning revisions were warranted.
FDA Approval Does Not Automatically Preempt State Failure-to-Warn Claims
The Supreme Court clarified that FDA drug label approval sets a regulatory floor, not a ceiling, allowing state tort claims to proceed when warnings are alleged to be inadequate. Drug manufacturers remain responsible for ensuring their labeling reflects known safety risks, even post-approval. Attorneys should assess both federal compliance and whether safer warnings could have been independently implemented.
Use of the “Changes Being Effected” (CBE) Rule Strengthens Plaintiff Claims
Plaintiff arguments were reinforced by showing that Wyeth could have strengthened Phenergan’s warning label through the FDA’s CBE regulation without prior agency approval. This undermined the defendant’s preemption defense and highlighted regulatory pathways for proactive labeling changes. Legal teams should understand and leverage CBE provisions when arguing liability in drug labeling cases.
Expert Testimony on Administration Risk and Label Clarity Is Pivotal
Medical safety and pharmaceutical labeling experts helped the jury evaluate whether IV-push administration posed foreseeable risks and if the label addressed those risks sufficiently. Their technical insights were central to proving both causation and the inadequacy of the warnings. For litigators, carefully selecting experts with regulatory and clinical knowledge can significantly shape outcomes.
Prior Adverse Event Data Can Establish Foreseeability and Liability
The case referenced more than 20 prior amputations involving Phenergan, demonstrating that Wyeth had access to significant safety signals. Establishing a pattern of harm can be critical in proving that a manufacturer knew or should have known of the risks. Attorneys should investigate adverse event databases and internal drug safety monitoring records to support claims.
Preemption Defenses Must Consider Both Regulatory History and Manufacturer Conduct
While Wyeth relied on a 2006 FDA preamble asserting preemption, the Court focused on the broader statutory framework and the company’s actions. Preemption arguments require a fact-intensive analysis of label history, agency correspondence, and manufacturer discretion. Defense counsel should not rely solely on FDA approval but must show a clear conflict between federal requirements and proposed state actions.
The Wyeth v. Levine decision remains a landmark case in the intersection of product liability and pharmaceutical regulation, establishing that drug manufacturers can be held liable under state law for inadequate warnings, even when those labels have FDA approval. The case began with a tragic injury involving IV-push administration of Phenergan and evolved into a high-stakes legal battle over whether federal regulation shields drug companies from state tort claims. Through compelling expert testimony and a decisive Supreme Court ruling, the case affirmed the rights of injured individuals to seek remedies when warnings fail to fully inform medical risks.
The broader implications for drug injury litigation are significant, particularly in how courts interpret the FDA’s role in labeling oversight. The Supreme Court’s ruling clarified that FDA approval does not absolve manufacturers of their responsibility to strengthen warnings when new risks emerge. Attorneys litigating pharmaceutical injury cases must understand not only the nuances of federal labeling requirements but also how to argue for state-level accountability when safety concerns go unaddressed. Wyeth v. Levine continues to shape the strategic and regulatory landscape of pharmaceutical litigation across the United States.
What was Wyeth v. Levine about?
Wyeth v. Levine was a U.S. Supreme Court case involving a woman who lost her arm due to an improperly administered drug, Phenergan. She sued the drug manufacturer, Wyeth, alleging the label failed to provide adequate warnings. The legal issue centered on whether FDA approval of the label shielded Wyeth from liability under state law.
Did the Supreme Court rule in favor of Diana Levine?
Yes, the U.S. Supreme Court ruled 6–3 in favor of Diana Levine. The Court held that FDA approval of a drug label does not preempt state-law failure-to-warn claims. This allowed Levine to recover damages under Vermont law.
Why is Wyeth v. Levine considered a landmark case?
The case set a precedent on the limits of federal preemption in pharmaceutical litigation. It confirmed that drug manufacturers can be held liable under state law even if their labeling complies with FDA requirements. This decision has influenced numerous drug injury lawsuits nationwide.
What is the “Changes Being Effected” (CBE) regulation?
The CBE regulation allows drug manufacturers to update warning labels without prior FDA approval when new safety information becomes available. This rule was central in the Court’s reasoning in Wyeth v. Levine. It showed Wyeth had the authority to strengthen its warning label to address known risks.
How did Phenergan cause Diana Levine’s injury?
Phenergan was administered via the IV-push method, which accidentally introduced the drug into an artery. This caused tissue damage and gangrene, resulting in the amputation of Levine’s arm. The plaintiff argued the drug label failed to sufficiently warn against this known risk.
What impact did the FDA’s stance have on the case?
Drug Labels Expert Witness
Drug Label Experts assessed whether the Phenergan label adequately communicated the risks associated with IV-push administration. They analyzed the content, clarity, and prominence of the warning language, focusing on whether the label sufficiently informed clinicians of known dangers.
The plaintiff’s expert argued that the label should have explicitly discouraged IV-push use, while Wyeth’s expert maintained that the FDA-approved language was appropriate. Their testimony centered on how stronger or more specific warnings might have altered the method of drug administration and prevented harm.
Medical Expert Witness
Medical Experts in Wyeth v. Levine provided testimony on the technical risks of intravenous drug delivery, focusing on whether the IV-push method posed foreseeable vascular hazards. These experts did not assess treatment errors or standard of care broadly but instead evaluated how administration techniques interact with drug characteristics and labeling. Their role was critical in connecting label warnings to the resulting physical injury. While their domain overlaps with clinical practice, their involvement in this case was limited to drug safety and administration protocol.
Food and Drug Administration (FDA) Expert Witness
FDA experts are often engaged in drug labeling litigation to clarify how Food and Drug Administration processes affect manufacturer responsibilities. In such cases, the legal debate centered on whether FDA approval of Phenergan’s label preempted state failure-to-warn claims, with key focus on the “Changes Being Effected” (CBE) regulation. Litigation of this nature often involves former FDA staff or regulatory consultants to explain the agency’s approval authority, preemption stance, and risk communication standards.
Drug Research Expert Witness
Drug research experts are commonly engaged in pharmaceutical litigation to assess how adverse events are monitored, reported, and acted upon during a drug’s life cycle. These experts often examine post-marketing surveillance data, FDA safety reporting practices, and clinical pharmacology to evaluate whether warning revisions were warranted.
FDA Approval Does Not Automatically Preempt State Failure-to-Warn Claims
The Supreme Court clarified that FDA drug label approval sets a regulatory floor, not a ceiling, allowing state tort claims to proceed when warnings are alleged to be inadequate. Drug manufacturers remain responsible for ensuring their labeling reflects known safety risks, even post-approval. Attorneys should assess both federal compliance and whether safer warnings could have been independently implemented.
Use of the “Changes Being Effected” (CBE) Rule Strengthens Plaintiff Claims
Plaintiff arguments were reinforced by showing that Wyeth could have strengthened Phenergan’s warning label through the FDA’s CBE regulation without prior agency approval. This undermined the defendant’s preemption defense and highlighted regulatory pathways for proactive labeling changes. Legal teams should understand and leverage CBE provisions when arguing liability in drug labeling cases.
Expert Testimony on Administration Risk and Label Clarity Is Pivotal
Medical safety and pharmaceutical labeling experts helped the jury evaluate whether IV-push administration posed foreseeable risks and if the label addressed those risks sufficiently. Their technical insights were central to proving both causation and the inadequacy of the warnings. For litigators, carefully selecting experts with regulatory and clinical knowledge can significantly shape outcomes.
Prior Adverse Event Data Can Establish Foreseeability and Liability
The case referenced more than 20 prior amputations involving Phenergan, demonstrating that Wyeth had access to significant safety signals. Establishing a pattern of harm can be critical in proving that a manufacturer knew or should have known of the risks. Attorneys should investigate adverse event databases and internal drug safety monitoring records to support claims.
Preemption Defenses Must Consider Both Regulatory History and Manufacturer Conduct
While Wyeth relied on a 2006 FDA preamble asserting preemption, the Court focused on the broader statutory framework and the company’s actions. Preemption arguments require a fact-intensive analysis of label history, agency correspondence, and manufacturer discretion. Defense counsel should not rely solely on FDA approval but must show a clear conflict between federal requirements and proposed state actions.
The Wyeth v. Levine decision remains a landmark case in the intersection of product liability and pharmaceutical regulation, establishing that drug manufacturers can be held liable under state law for inadequate warnings, even when those labels have FDA approval. The case began with a tragic injury involving IV-push administration of Phenergan and evolved into a high-stakes legal battle over whether federal regulation shields drug companies from state tort claims. Through compelling expert testimony and a decisive Supreme Court ruling, the case affirmed the rights of injured individuals to seek remedies when warnings fail to fully inform medical risks.
The broader implications for drug injury litigation are significant, particularly in how courts interpret the FDA’s role in labeling oversight. The Supreme Court’s ruling clarified that FDA approval does not absolve manufacturers of their responsibility to strengthen warnings when new risks emerge. Attorneys litigating pharmaceutical injury cases must understand not only the nuances of federal labeling requirements but also how to argue for state-level accountability when safety concerns go unaddressed. Wyeth v. Levine continues to shape the strategic and regulatory landscape of pharmaceutical litigation across the United States.
What was Wyeth v. Levine about?
Wyeth v. Levine was a U.S. Supreme Court case involving a woman who lost her arm due to an improperly administered drug, Phenergan. She sued the drug manufacturer, Wyeth, alleging the label failed to provide adequate warnings. The legal issue centered on whether FDA approval of the label shielded Wyeth from liability under state law.
Did the Supreme Court rule in favor of Diana Levine?
Yes, the U.S. Supreme Court ruled 6–3 in favor of Diana Levine. The Court held that FDA approval of a drug label does not preempt state-law failure-to-warn claims. This allowed Levine to recover damages under Vermont law.
Why is Wyeth v. Levine considered a landmark case?
The case set a precedent on the limits of federal preemption in pharmaceutical litigation. It confirmed that drug manufacturers can be held liable under state law even if their labeling complies with FDA requirements. This decision has influenced numerous drug injury lawsuits nationwide.
What is the “Changes Being Effected” (CBE) regulation?
The CBE regulation allows drug manufacturers to update warning labels without prior FDA approval when new safety information becomes available. This rule was central in the Court’s reasoning in Wyeth v. Levine. It showed Wyeth had the authority to strengthen its warning label to address known risks.
How did Phenergan cause Diana Levine’s injury?
Phenergan was administered via the IV-push method, which accidentally introduced the drug into an artery. This caused tissue damage and gangrene, resulting in the amputation of Levine’s arm. The plaintiff argued the drug label failed to sufficiently warn against this known risk.
What impact did the FDA’s stance have on the case?
Although the FDA had approved the drug’s label, the Court determined that such approval did not eliminate Wyeth’s duty to ensure the label remained adequate. The agency’s 2006 preamble supporting preemption was considered but ultimately not persuasive. The decision reinforced that FDA approval does not automatically override state law remedies.
Drug Labels
FDA Regulation
Drug Regulation
Pharmaceutical Product Liability
Safety Warnings
Adverse Event
Drug Research
Pharmacotherapy
Pharmaceutical, +4
Pharmaceutical
Securities, +4
Pharmaceutical
Although the FDA had approved the drug’s label, the Court determined that such approval did not eliminate Wyeth’s duty to ensure the label remained adequate. The agency’s 2006 preamble supporting preemption was considered but ultimately not persuasive. The decision reinforced that FDA approval does not automatically override state law remedies.